Patents by Inventor Susanne MOHR

Susanne MOHR has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Enhanced oligonucleotides for inhibiting RTEL1 expression
    Patent number: 11898145
    Abstract: The present disclosure provides antisense oligonucleotides targeting Regulator of telomere elongation helicase 1 (RTEL1). The disclosure also provides, enhanced antisense oligonucleotides targeting RTEL1 for use in treating and/or preventing a hepatitis B virus (HBV) infection. Also disclosed are pharmaceutical compositions and their use.
    Type: Grant
    Filed: February 1, 2022
    Date of Patent: February 13, 2024
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Erik Funder, Natascha Hruschka, Susanne Kammler, Erich Koller, Brian Leonard, Souphalone Luangsay, Susanne Mohr, Tobias Nilsson, Søren Ottosen, Lykke Pedersen, Søren V. Rasmussen, Steffen Schmidt, Sabine Sewing, Daniel Turley, Johanna Marie Walther
  • ENHANCED OLIGONUCLEOTIDES FOR INHIBITING RTEL1 EXPRESSION
    Publication number: 20220251556
    Abstract: Enhanced antisense oligonucleotides targeting Regulator of telomere elongation helicase 1 (RTEL1), leading to modulation of the expression of RTEL1 or modulation of RTEL1 activity are provided. This disclosure relates to the use of enhanced antisense oligonucleotides targeting RTEL1 for use in treating and/or preventing a hepatitis B virus (HBV) infection, in particular a chronic HBV infection. This disclosure further relates to the use of the enhanced antisense oligonucleotides targeting RTEL1 for destabilizing cccDNA, such as HBV cccDNA. A pharmaceutical composition and its use in the treatment and/or prevention of a HBV infection is also described.
    Type: Application
    Filed: February 1, 2022
    Publication date: August 11, 2022
    Applicant: HOFFMANN-LA ROCHE INC.
    Inventors: Erik FUNDER, Natascha HRUSCHKA, Susanne KAMMLER, Erich KOLLER, Brian LEONARD, Souphalone LUANGSAY, Susanne MOHR, Tobias NILSSON, Søren OTTOSEN, Lykke PEDERSEN, Søren V. RASMUSSEN, Steffen SCHMIDT, Sabine SEWING, Daniel TURLEY, Johanna Marie WALTHER
  • ENHANCED OLIGONUCLEOTIDES FOR MODULATING FUBP1 EXPRESSION
    Publication number: 20220031730
    Abstract: The present invention relates to enhanced antisense oligonucleotides that are complementary to the Far Upstream Element-Binding Protein 1 (FUBP1) and are capable of reducing a FUBP1 target nucleic acid, such as FUBP1 mRNA. The invention relates to enhanced antisense oligonucleotides targeting FUBP1 or conjugates thereof for use in treating and/or preventing a hepatitis B virus (HBV) infection, in particular a chronic HBV infection. The invention in particular relates to the use of the enhanced antisense oligonucleotides targeting FUBP1 or conjugates thereof for destabilizing cccDNA, such as HBV cccDNA. The invention further relates to enhanced antisense oligonucleotides targeting FUBP1 or conjugates thereof for use in treating cancer. A pharmaceutical composition and its use in the treatment and/or prevention of an HBV infection, or its use in the treatment of cancer is also disclosed.
    Type: Application
    Filed: June 25, 2021
    Publication date: February 3, 2022
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Sabine SEWING, Søren OTTOSEN, Jacob RAVN, Lykke PEDERSEN, Souphalone LUANGSAY, Erich KOLLER, Johanna Marie WALTHER, Helene Maria GYLLING, Natascha HRUSCHKA, Susanne MOHR, Valentina D'ARIENZO